These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26745646)

  • 1. Regression of ventriculomegaly following medical management of a patient with Hurler syndrome.
    Liang J; Singhal A
    J Neurosurg Pediatr; 2016 May; 17(5):537-9. PubMed ID: 26745646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
    Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
    Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome.
    Bijarnia S; Shaw P; Vimpani A; Smith R; Pacey V; O'Grady H; Christodoulou J; Sillence D
    J Paediatr Child Health; 2009; 45(7-8):469-72. PubMed ID: 19712183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
    Thomas JA; Jacobs S; Kierstein J; Van Hove J
    J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Remmington T
    Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of organ manifestations upon enzyme replacement therapy in a patient with mucopolysaccharidosis type I/Hurler.
    Mercimek-Mahmutoglu S; Reilly C; Human D; Waters PJ; Stoeckler-Ipsiroglu S
    World J Pediatr; 2009 Nov; 5(4):319-21. PubMed ID: 19911152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell transplantation effects on spinal cord compression in Hurler.
    Ferrara G; Maximova N; Zennaro F; Gregori M; Tamaro P
    Pediatr Transplant; 2014 May; 18(3):E96-9. PubMed ID: 24483599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.
    Illsinger S; Lücke T; Hartmann H; Mengel E; Müller-Forell W; Donnerstag F; Das AM
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S321-5. PubMed ID: 19894140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Wraith JE
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of rehabilitation in Hurler's syndrome.
    Mishra SR; Shastri M; Ramesh J
    J Back Musculoskelet Rehabil; 2017; 30(3):635-639. PubMed ID: 27911282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of severe heart failure in an infant with Hurler syndrome.
    Hirth A; Berg A; Greve G
    J Inherit Metab Dis; 2007 Oct; 30(5):820. PubMed ID: 17768668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome.
    Grewal SS; Wynn R; Abdenur JE; Burton BK; Gharib M; Haase C; Hayashi RJ; Shenoy S; Sillence D; Tiller GE; Dudek ME; van Royen-Kerkhof A; Wraith JE; Woodard P; Young GA; Wulffraat N; Whitley CB; Peters C
    Genet Med; 2005 Feb; 7(2):143-6. PubMed ID: 15714083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan.
    Tanaka A; Okuyama T; Suzuki Y; Sakai N; Takakura H; Sawada T; Tanaka T; Otomo T; Ohashi T; Ishige-Wada M; Yabe H; Ohura T; Suzuki N; Kato K; Adachi S; Kobayashi R; Mugishima H; Kato S
    Mol Genet Metab; 2012 Nov; 107(3):513-20. PubMed ID: 23022072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy.
    Gonzalez EA; Visioli F; Pasqualim G; de Souza CFM; Marinho DR; Giugliani R; Matte U; Baldo G
    Clin Exp Ophthalmol; 2020 Apr; 48(3):334-342. PubMed ID: 31925897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
    Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
    Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome.
    Tolar J; Grewal SS; Bjoraker KJ; Whitley CB; Shapiro EG; Charnas L; Orchard PJ
    Bone Marrow Transplant; 2008 Mar; 41(6):531-5. PubMed ID: 18037941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open issues in Mucopolysaccharidosis type I-Hurler.
    Parini R; Deodato F; Di Rocco M; Lanino E; Locatelli F; Messina C; Rovelli A; Scarpa M
    Orphanet J Rare Dis; 2017 Jun; 12(1):112. PubMed ID: 28619065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.
    Chiaro JA; O'Donnell P; Shore EM; Malhotra NR; Ponder KP; Haskins ME; Smith LJ
    J Bone Miner Res; 2014 Dec; 29(12):2610-7. PubMed ID: 24898323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
    Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
    J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.